Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma

Journal of Asthma

Volumn 42, Issue 10, 2005, Pages 865-871

  Pinnas, Jacob L ^a,f   Noonan, Michael J ^b   Weinstein, Steven F ^c   Chervinsky, Paul ^d   Scott, Catherine A ^e   Herje, Nancy E ^e   Wu, Wei ^e   Crim, Courtney ^e  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Allergy Associates Research Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d New England Clinical Studies   (United States)

^e GLAXOSMITHKLINE   (United States)

^f Allergy Center of Arizona   (United States)

Author keywords

Asthma; Cortisol; Fluticasone propionate; Hydrofluoroalkane; Inhaled corticosteroids

Indexed keywords

FLUTICASONE PROPIONATE; HYDROCORTISONE; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; BRONCHITIS; CANDIDIASIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG SAFETY; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HOARSENESS; HUMAN; HYDROCORTISONE URINE LEVEL; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; METERED DOSE INHALER; MODERATE PERSISTENT ASTHMA; MULTICENTER STUDY; MUSCLE INJURY; PATIENT ASSESSMENT; PEAK EXPIRATORY FLOW; RANDOMIZED CONTROLLED TRIAL; SEVERE PERSISTENT ASTHMA; THROAT IRRITATION; THRUSH; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION; VIRAL RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AEROSOL PROPELLANTS; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; HYDROCORTISONE; MALE; METERED DOSE INHALERS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 30344486943     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900500371294     Document Type: Article

References (16)

1. Atkins P. Chlorofluorocarbon to hydrofluoroalkane formulations: An industry perspective. J Allergy Clin Immunol 1999; 104:S268-S270.
2. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. U.S. Department of Health and Human Services, National Institutes of Health, NIH Publication No. 97-4051, Bethesda, Maryland, 1997.
3. Ayres JG, Millar AB, Sykes AP. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA-134a pressurized metered dose inhaler to patients with severe asthma. Respir Med 2000; 94(suppl B):S42-S50.
4. Tonnel AB, Bons J, Legendre M, Prud'Homme A, Bugnas B, Evano-Celli I, et al. Clinical efficacy and safety of fluticasone propionate 250 μg twice daily administered via a HFA-134a pressurized metered dose inhaler to patients with mild to moderate asthma. Respir Med 2000; 94(suppl B):S29-S34.
5. Perruchoud AP, Lundback B, YiglaM, Sikes AP. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA-134a pressurized metered-dose inhaler to patients with moderate to severe asthma. Respir Med 2000; 94(suppl B):S35-S41.
6. Flovent® 44 μg, 110 μg, 220 μg Inhalation Aerosol Package Insert. GlaxoSmithKline, Research Triangle Park, NC, March 2004.
7. Szefler SJ, Boushey HA, Pearlman DS, Togias A, Liddle R, Furlong A, et al. Time to onset of effect of fluticasone propionate in patients with asthma. J Allergy Clin Immunol 1999; 103:780-788.
8. Pearlman DS, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol 1999; 82:257-265.
9. Chervinsky P, van As A, Bronsky EA, Dockhorn R, Noonan M, LaForce C, et al. Fluticasone propionate aerosol for the treatment of adults with mild-to-moderate asthma. J Allergy Clin Immunol 1994; 94:676-683.
10. Wolfe JD, Selner JC, Mendelson LM, Hampel F Jr, Schaberg A. Effectiveness of fluticasone propionate in patients with moderate asthma: A dose-ranging study. Clin Ther 1996; 18:635-646.
11. Galant SP, Lawrence M, Meltzer EO, Tomasko M, Baker KA, Kellerman DJ. Fluticasone propionate compared with theophylline for mild-to-moderate asthma. Ann Allergy Asthma Immunol 1996; 77:112-118.
12. Sheffer AL, LaForce C, Chervinsky P, Pearlman D, Schaberg A. Fluticasone propionate aerosol: Efficacy in patients with mild-to-moderate asthma. J Fam Pract 1996; 42:369-375.
13. Noonan MJ, Chervinsky P, Wolfe J, Liddle R, Kellerman DJ, Crescenzi KL. Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: A double-blind, placebo-controlled study. J Asthma 1998; 35:153-164.
14. Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000; 94(suppl B):S3-S9.
15. Li JT, Ford LB, Chervinsky P, Weisberg SC, Kellerman DJ, Faulkner KG, et al. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol 1999; 103:1062-1068.
16. Kemp JP, Osur S, Shrewsbury SB, Herje NE, Duke SP, Harding SM, et al. Potential effects of fluticasone propionate on bone mineral density in patients with asthma: A 2-year randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004; 79(4):458-466.